Surge in IgA Nephropathy Disorder Drive the Demand for IgA Nephropathy Market

 

IgA nephropathy, also known as Buerger's disease, is a kidney disease that occurs when IgA concentration builds up in the kidneys, causing inflammation that damages the kidney tissues. It is an orphan disease, designated as an orphan indication in both the U.S. and Europe. According to the report updated in May 2019, about 10% of the biopsies performed for glomerular disease (GD) are for IgA nephropathy in the United States. The number of patients infected with IgA disorder is increasing, and this increases the chances of multiple complications associated with it. Thus, the rising number contributes to the IgA prevalence worldwide, leading to the increasing demand for IgA nephropathy treatment products. Thus, the global rise in IgA nephropathy disorder acts as a driver for global IgA nephropathy market growth.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-iga-nephropathy-market

Data Bridge Market Research analyses that the IgA nephropathy market is expected to grow at a CAGR of 9.2% in the forecast period of 2021 to 2028 and is expected to reach USD 9,124.84 million by 2028. The companies are investing a huge amount for their research & development program and have shown some strategic initiatives in which, during the pandemic the Chinook therapeutics have to increase the funding for R & D. The increasing research and development for the IgA nephropathy will act as a driver for the forecast period in global IgA nephropathy market.

IgA Nephropathy Market

Increasing government Funding for Research Purposes is expected to drive the market's growth rate

The government provides research grants to help organizations ready to participate in drug discovery and development for that disease. Various organizations focused on a particular disease, In IgA neuropathy, IgA Nephropathy Foundation's, National Kidney Foundation Inc., Renal Pathology Society, among others, are some of the above-mentioned disorders. According to a report in 2019, Ventures capitalists are financing a crop of startups seeking to revolutionize a kidney disease. They are making huge investments in kidney research, which is expected to be an opportunity for market research. The increased investment and funding by government organization and other private investment agencies will increase the opportunities for the market and fuel up the global IgA nephropathy market in the forecasted period.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020(Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Dressing, Therapy Device, Biologics, Others), Wound Type (Primary Wound Care, Secondary Wound Care), Wound Class (Class I, Class II, Class III, Class IV), End User (Hospitals, Wound Care Centres, Ambulatory Centres, Home Healthcare, Clinics, Others), Distribution Channel (Direct Tenders, Retail)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Siemens Healthcare GmbH (Germany), Zydus Cadila (India), Hikma Pharmaceuticals PLC (U.K.), LEO Pharma A/S (Denmark), Fresenius Kabi AG (Germany), Accord Healthcare (U.S.), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Alembic Pharmaceuticals Limited (India), Apotex Inc. (Canada)

Data Points Covered in Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

Global IgA nephropathy market is categorized into seven notable segments which are based on the disease type, symptoms, type, population type, route of administration, end user and distribution channel.

  • On the basis of disease type, global IgA nephropathy market is segmented into primary IgA nephropathy and secondary IgA nephropathy. In 2021, the primary IgA nephropathy segment is expected to dominate the market, with the highest CAGR of 9.4% in the forecast period of 2021 to 2028 because the incidence of primary IgA nephropathy is more and can be diagnosed by blood or urine test easily. Secondary IgAN affect other related organ than kidney which is somewhat rare due to which it has low incidence rate.
  • On the basis of symptoms, global IgA nephropathy market is segmented into hematuria, proteinuria, edema and others. In 2021, hematuria segment is expected to dominate the market growing with the highest CAGR of 9.4% in the forecast period of 2021 to 2028 as it is the most common and frequently used parameter for clinical examination and is detected by the amount of blood in the urine showing the occurrence of disease in the kidney.
  • On the basis of type, global IgA nephropathy market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market growing with the highest CAGR of 9.3%.

The diagnosis segment is expected to dominate the market growing with the highest CAGR of 9.3%

In 2021, the diagnosis segment is expected to dominate the market growing with the highest CAGR of 9.3% in the forecast period of 2021 to 2028 due to the fact that prior given the treatment, the proper detection and tracing of the IgA nephropathy is necessary which is possible only through the primary detection such as blood and urine test and confirmatory detection by kidney biopsy which are the major factor of this segment to dominate.

  • On the basis of population type, global IgA nephropathy market is segmented into pediatrics and adults. In 2021, the adults segment is expected to show the significant growth growing with the highest CAGR of 9.1% in the forecast period of 2021 to 2028 because the studies showed the connection of this disease with ageing. With ageing, the amount of protein in the kidney started to build at a certain concentration with time and is a common problem in younger and elderly adults. The adults segment is dominating the market.
  • On the basis of route of administration, global IgA nephropathy market is segmented into oral, parenteral and others. Oral segment is further segmented into tablet, pills and others. Parenteral segment is further segmented into intramuscular, intravenous and others, In 2021, the oral segment is expected to dominate the market growing with the highest CAGR of 9.3% in the forecast period of 2021 to 2028 due to the wide variety of oral product portfolio available in the interstate commerce by the market which increase the market of this segment.
  • On the basis of end user, global IgA nephropathy market is segmented into hospitals, clinics, home healthcare and others. In 2021, hospitals segment is expected to dominate the market growing with the highest CAGR of 9.7%.

The hospitals segment is expected to dominate the market growing with the highest CAGR of 9.7%

In 2021, the hospitals segment is expected to dominate the market, with the highest CAGR of 9.7% in the forecast period of 2021 to 2028 due to its strong financial structure. The hospitals segment is growing due to the presence of trained professionals. The hospitals department has well-trained staff with a professional team for proper and better diagnosis and treatment of the patients. The major driving factor is that they provide communal benefits with more patient satisfaction.

  • On the basis of distribution channel, global IgA nephropathy market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment dominates the market, growing with the highest CAGR of 9.4% in the forecast period of 2021 to 2028 owing to which the direct tender segment is flourishing for the last few years, henceforth, affirmative illustrating the further growth of the market.

Major Players

Data Bridge Market Research recognizes the following companies as the major IgA nephropathy market players in IgA nephropathy market are AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Siemens Healthcare GmbH (Germany), Zydus Cadila (India), Hikma Pharmaceuticals PLC (U.K.), LEO Pharma A/S (Denmark), Fresenius Kabi AG (Germany), Accord Healthcare (U.S.), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Alembic Pharmaceuticals Limited (India), Apotex Inc. (Canada).

IgA Nephropathy Market

Market Development

  • In March 2021, Evotec SE and Chinook Therapeutics announced a strategic collaboration focused on discovering and developing novel precision medicine therapies for patients with chronic kidney diseases ("CKD") such as IgA nephropathy. The collaboration leverages Evotec's proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging for this disease mentioned above
  • In December 2020, CareDx announced the positive outcomes from the first publication of the use of AlloSure in pediatric patients who have kidney transplant. This publication ensures that AlloSure has the efficacy to manage the high-need population relying on kidney transplantation and subjected to graft rejection. The result obtained allowed the company to serve large scale pediatric patients and to earn a potential growth in the market
  • In December 2021, United States Food and Drug Administration (FDA) announced the approval of the first drug to decrease urine protein in IgA nephropathy, a rare kidney disease. Tarpeyo (budesonide) delayed release capsules have been given fast approval by the FDA to reduce proteinuria (increased protein levels in the urine) in people with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression. Tarpeyo has not been proven to halt the decrease of kidney function in people with IgA nephropathy
  • In October 2020, Novartis AG received an orphan drug designation for Iptacopan (LNP023) in IgA nephropathy (IgAN) by European Medicines Agency. It also received a recommendation from the Committee for Orphan Medicinal Products (COMP) in Basel. The orphan drug designation is granted to medicines that cure a rare chronic disease. The approval received would result in swift distribution of the drugs in hospitals and kidney diagnostic centers in Europe. It would deliver positive growth in the market

Regional Analysis

Geographically, the countries covered in the IgA nephropathy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in IgA nephropathy market during the forecast period

North America dominated the IgA nephropathy market due to U.S. manufacturers' higher level of investments. North America will continue to dominate the IgA nephropathy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the rising demand for IgA nephropathy products in this region. 

Asia-Pacific is estimated to be the fastest-growing region in IgA nephropathy market

Asia-Pacific is expected to grow during the forecast period due to the presence of major market players and rising government initiatives in this region. In addition to this, development of healthcare infrastructure is expected propel the market's growth rate in this region.

How does high cost of the treatment procedure further impact overall growth rate of the market?

The treatment cost of the particular disease is mainly seen as the restraint for the market or a factor that can limit growth. IgA nephropathy treatment comprises diagnosis and further treatment with various drugs, starting from blood pressure-lowering agents, immunosuppressive agents, cholesterol lowering, and various supplements. The disease diagnosis has various blood tests, urinalysis and some radioactive tests, and the most important kidney biopsy. The total cost of treatment or the cumulative expense of diagnosis and treatment is quite high. The below-given instance will describe the cost per pocket if the reimbursement is not provided, which is a major drawback in emerging countries. For instance, The Average cost of kidney biopsy in the U.S. is USD 4,995, the estimated national average for the U.S. Moreover, the biopsy is the most accurate and optimum test for the diagnosis of IgA nephropathy. Although the test price is high, which is expected to limit the use of biopsies and hinder the market growth. Hence, the cost of treatment and diagnosis is expected to be one of the major factors. The demand is supposed to decrease, which will negatively impact the market and act as a restraint for the market growth in the forecast period.

For more detailed information about the IgA nephropathy market report, click here – https://www.databridgemarketresearch.com/reports/global-iga-nephropathy-market